Formycon AG (XTER:FYB)

Q3 2025 Formycon AG Earnings Call Transcript

Nov 13, 2025 / 02:00 PM GMT

Release Date Price: €21 (-2.78%)

Transcript

Key Points

Positve

Formycon AG (XTER:FYB) successfully completed patient recruitment for its phase 1 clinical trial of the Keytruda biosimilar, positioning the company competitively in the PD1 oncology segment.
The company reaffirmed its full-year guidance across all key financial indicators, indicating confidence in its financial performance.
Formycon AG achieved significant operational milestones, including the introduction of the first ranibizumab biosimilar in a specially designed ophthalmic prefilled syringe.
The company is leveraging recent regulatory movements towards streamlining biosimilar development, which promotes faster and more cost-efficient pathways.
Formycon AG has established a strong commercial presence, with products launched in 20 countries and market penetration progressing in key European markets.

Negative

Revenues for the first nine months of 2025 were lower compared to the same period in 2024, reflecting a transformation in revenue structure.
The company anticipates a backloaded revenue performance in 2025, with significant reliance on Q4 for meeting full-year guidance.
Costs of sales increased compared to Q3 2024, primarily due to amortization expenses related to F-22.
Adjusted EBITDA declined significantly due to reduced equity results from the joint venture BOA, impacted by paused US activities.
The company faces challenges in market penetration, particularly in the US, where biosimilar adoption is incremental and not immediate.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

FYB.DE - Formycon AG
Q3 2025 Formycon AG Earnings Call
Nov 13, 2025 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon ladies and gentlemen, and welcome to the For Econ AG earnings call 9 months 2025. At this time, all participants have been placed on a list only remote.

The floor will be open for your questions following the presentation.

Let me now turn the floor over to Stefan Glomwitzer, the CEO of Formicon.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Yeah, thank you for the introduction, Beatrice. Good afternoon, good morning, and warm welcome also from my side.

We appreciate your attendance and interest as always in Formicon's Q3 earnings call.

Earlier

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.